FARMER BROTHERS CO

FARM
Country: United StatesPrice: $1.25Market Cap: $26.6M

Investment snapshot

6%positive consensus
Scored 1d ago

Positive

1

BUY / PASS

Neutral / negative

2 / 13

NEUTRAL / FAIL

Median fair value

—

No comparable estimates

Models with upside

0 / 17

Positive margin of safety

Key risk

No clean pass — all 13 investors flag at least one valuation criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILFAIL · Rank #2034 (Top 65.7%)FAILFAILFAILFAILFAILFAILFAILPASSFAILNEUTRALFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Financial Basis

TTM ended 2025-12-31 · Balance sheet at 2025-12-31 · Annual history · FY 2025

Latest source filing: 2026-02-13

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2025-12-31

Latest source filing: 2026-02-13

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2025-12-31 · TTM ended 2025-12-31 vs 2024-12-31 · TTM ended 2025-12-31

Latest source filing: 2026-02-13

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2025-09-11

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2025-09-11

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2025-12-31 · Balance sheet at 2025-12-31 · Market data at 2026-04-10

Latest source filing: 2026-02-13

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025 · TTM ended 2025-12-31 · Balance sheet at 2025-12-31

Latest source filing: 2026-02-13

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2025-09-11

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment · Balance sheet at 2025-12-31

Latest source filing: 2026-02-13

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2025-12-31 · Qualitative assessment

Latest source filing: 2026-02-13

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2025-12-31 · Balance sheet at 2025-12-31 · Market data at 2026-04-10

Latest source filing: 2026-02-13

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-04-10 · Balance sheet at 2025-12-31

Latest source filing: 2026-02-13

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2025-09-11

Score computed: 2026-11-14

TTM ended 2025-12-31 · Balance sheet at 2025-12-31 · Price history 2025-01-01–2026-04-10 · Annual history · FY 2025

Latest source filing: 2026-02-13

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2025-09-11

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2025-12-31

Latest source filing: 2026-02-13

Score computed: 2026-11-14

TTM ended 2025-12-31 · Annual history · FY 2025 · Price history 2025-01-01–2026-04-10

Latest source filing: 2026-02-13

Score computed: 2026-11-14

Where It Passes

    Where It Falls Short

    • Valuation0% pass✓ 9✗ 19▾

      No clean pass — all 13 investors flag at least one valuation criterion

      Price / 3-yr avg EPS
      ✗Graham<= 15x
      Price-to-Book Ratio0.6x
      ✓Graham<= 1.5x
      P/E x P/B
      ✗Graham<= 22.5
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      EBIT / Enterprise Value-7.4%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-7.4%, ROC=-4.1%
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Price / EPS
      ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
      Price / (CFO / Shares)1.7x
      ✓Dreman< 8x
      Price / Book Value per Share0.6x
      ✓Dreman< 1.2x✓Templeton< 1.5x✓SchlossP/B <= 0.80x (app cutoff)
      Valuation ReasonablenessOE Yield=-11.4%
      ✗MungerP/E < 25 or Owner Earnings Yield > 5%
      P/E or FCF Yield
      ✗PabraiP/E < 15 or FCF Yield > 10%
      P/B or P/E vs. Historical AverageP/B=0.6x
      ✓MarksP/E < 15 or P/B < 2.0
      Discount to Intrinsic ValueN/A (negative normalized EPS)
      ✗Marks>= 20% below intrinsic value
      Price / FCF per Share
      ✗Ackman<= 25
      Price vs. Trailing Low
      ✗Templeton<= 120% of trailing low (certified split-adjusted live window)
      Net income / market capitalization-70.03%; #5221/6340 (top 82.4%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Positive book equity / market capitalization+1.3415; #1051/6449 (top 16.3%)
      ✓AsnessTop 30% of eligible cross-section
      Price / Diluted EPS
      ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
      (EPS CAGR % + Dividend Yield %) / P/E
      ✗Neff> 0.7 (Neff's published traditional edge)
      Price / Tangible Book Value per Share0.62x
      ✓SchlossP/TBV <= 1.00x (app cutoff)
      Book Value per Share Change-66.7%
      ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
      Revenue / market capitalization+12.7056; #280/5247 (top 5.3%)
      ✓OshaughnessyTop 10% of eligible cross-section
      (Operating cash flow - capex) / market capitalization
      ✗OshaughnessyTop 10% of eligible cross-section
      Trailing six-month price return through the evaluation date
      ✗OshaughnessyTop 10% of eligible cross-section
    • Growth0% pass✓ 2✗ 11▾

      No clean pass — all 8 investors flag at least one growth criterion

      EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)
      ✗Graham>= 33% growth
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      Inventory Growth vs Revenue GrowthInv: -6.4% vs Rev: -2.1%
      ✓LynchInventory growth < Revenue growth
      EPS Growth Direction$-1.61 (2009) -> $-0.68 (2025)
      ✗DremanPositive over recent years
      EPS CAGR24.0% CAGR over 3 years
      ✓Dreman> 5% annualized
      Positive Net Income Frequency4/17 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      3yr Median Revenue Growth0.3%
      ✗Ackman>= 5%
      Positive EPS Growth Frequency2/5 years with positive EPS growth
      ✗AckmanPositive EPS growth in >= 3 of last 5 years
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Revenue growth vs. gross and operating margin trendgross margin 39.3% -> 43.5%, operating margin -0.7% -> -0.4%
      ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
      5-year Revenue CAGR5.5%
      ✗SleepCAGR > 7%
      3-5 Year Diluted EPS CAGR24.0% over 3 years
      ✗Neff7%-20% annualized
    • Efficiency0% pass✗ 11▾

      All 8 investors flag FARM's efficiency

      Current Ratio1.27
      ✗Graham>= 2.0
      ROIC (3-5 yr avg)-11.2%
      ✗Buffett> 10%
      ROIC - WACC-21.2%
      ✗BuffettPositive (WACC = 10%)
      EBIT / (NWC + Net Fixed Assets)-4.1%
      ✗Greenblatt> 25%
      Current Ratio Change YoY1.20 -> 1.20
      ✗PiotroskiIncreased YoY
      Revenue / Total Assets Change YoY2.12x -> 2.12x
      ✗PiotroskiImproved YoY
      Current Assets / Current Liabilities1.27
      ✗Dreman> 1.5
      Return on Invested Capital-15.4%
      ✗Munger> 15%
      ROIC (high and growing)FY2023: ROIC=-2.6%; FY2024: ROIC=-2.0%; FY2025: ROIC=unavailable
      ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
      Reinvestment Rate x ROIC
      ✗AkreReinvestment Rate * ROIC > 10%
      ROIC (5-year)0/4 years above 12% (latest -2.0%)
      ✗SleepROIC > 12% in a majority of years
    • Profitability6% pass✓ 4✗ 31▾

      15 of 16 flag FARM's profitability — Graham, Buffett, Lynch +12 more

      Positive EPS (10 years)4/18 years positive
      ✗GrahamPositive EPS every year for 10 years
      EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)
      ✗Graham>= 33% growth
      Net Income Positive (10+ years)4/18 years positive
      ✗BuffettPositive every year for 10+ years
      ROE (up to 5-year arithmetic mean)-59.6%
      ✗Buffett> 15% arithmetic mean (app rule)
      Operating Margin (10-yr trend)-0.4% (latest)
      ✗BuffettStable or rising over 10 years
      Free Cash Flow Proxy$-77.3M
      ✗BuffettPositive and growing
      Earnings Variance (10-yr CoV)N/A (negative mean EPS)
      ✗BuffettCoV < 0.3
      Retained Earnings Effectiveness
      ✗Buffett$1 retained -> > $1 market value created
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      ROE-52.2%
      ✗Lynch> 15%
      EBIT / Enterprise Value-7.4%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-7.4%, ROC=-4.1%
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Net Income / Total Assets-9.00%
      ✗PiotroskiROA > 0
      ROA Change YoY-9.00% -> -9.00% (delta: +0.00%)
      ✗PiotroskiCurrent ROA > Prior ROA
      (CFO / Total Assets) vs ROACFO/Assets=9.98%, ROA=-9.00%
      ✓PiotroskiCFO/Assets > ROA
      Gross Margin Change YoY43.5% -> 43.5%
      ✗PiotroskiImproved YoY
      Pre-Tax Income / Revenue-5.5%
      ✗Dreman>= 8%
      Net Income / Shareholders' Equity-52.2%
      ✗Dreman> 12%
      Margin of SafetyP/B=0.6x
      ✓PabraiP/B < 1.5 or P/E < 15
      Return on Equity-25.1% (3-yr avg)
      ✗AkreROE > 20% (3-year avg)
      Discount to Intrinsic ValueN/A (negative normalized EPS)
      ✗Marks>= 20% below intrinsic value
      Positive Net Income Frequency4/17 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      Operating Income / Revenue-2.1%
      ✗Ackman>= 15%
      Net Income / Shareholders Equity-52.2%
      ✗Ackman>= 15%
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Operating Margin Trend-0.7% (2023) -> -0.4% (2025)
      ✓TempletonNon-negative operating-margin trend over 3 years
      Revenue growth vs. gross and operating margin trendgross margin 39.3% -> 43.5%, operating margin -0.7% -> -0.4%
      ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
      Net income / market capitalization-70.03%; #5221/6340 (top 82.4%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Gross profit / total assets+90.76%; #174/3702 (top 4.7%)
      ✓AsnessTop 30% of eligible cross-section
      Net income / positive book equity-52.20%; #4227/5226 (top 80.9%)
      ✗AsnessTop 30% of eligible cross-section
      Negative 5-year standard deviation of ROA-0.1465; #3918/5884 (top 66.6%)
      ✗AsnessTop 30% of eligible cross-section
      3-5 Year Diluted EPS CAGR24.0% over 3 years
      ✗Neff7%-20% annualized
      Positive Diluted-EPS Years1/10 years positive
      ✗Schloss>= 70% positive over 5-10 observed years (app rule)
    • Verdicts7% pass✓ 1✗ 14▾

      Split decision: 13 FAIL · 2 NEUTRAL · 1 PASS

      Overall verdict
      ✗GrahamFAIL (2/9)✗BuffettFAIL (0/9)✗LynchFAIL (3/7)✗GreenblattRank #2034✗PiotroskiFAIL (F-Score 3)✗DremanFAIL (4/11)✗MungerFAIL (1/4)✗PabraiFAIL (1/3)✗AkreFAIL (1/6)✗MarksFAIL (2/5)✗AckmanFAIL (2/9)✓TempletonPASS (4/8)✗SleepFAIL (1/6)•AsnessNEUTRAL (Not ranked)✗NeffFAIL (1/6)✗SchlossFAIL (3/7)•OshaughnessyNEUTRAL (Not ranked)
    • Debt & Leverage50% pass✓ 9✗ 6▾

      6 of 12 pass — Graham, Buffett, Lynch +3 more object

      LT Debt vs Net Current Assets
      ✗GrahamLT Debt <= Net Current Assets
      Debt/Equity & Interest CoverageD/E: 0.00, IC: -1.1x
      ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
      Total Debt / Equity0
      ✓Lynch< 0.33
      Cash - Long-term Debt
      ✗LynchPositive preferred
      LT Debt / Total Assets Change0.00% -> 0.00%
      ✓PiotroskiDecreased YoY
      Current Assets / Current Liabilities1.27
      ✗Dreman> 1.5✗SchlossCurrent ratio >= 1.50x (app cutoff)
      Total Debt / Shareholders' Equity0
      ✓Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00x
      Debt Levels0
      ✓MungerDebt/Equity < 0.5✓AkreDebt/Equity < 0.3
      Interest Coverage & Debt/EBITDAIC=-1.1x, D/EBITDA=0.0x
      ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
      Total Debt / Shareholders Equity0
      ✓Ackman<= 1.0
      Negative debt-to-equity (higher means less debt)-0.0000; #1/4210 (top 0.0%)
      ✓AsnessTop 30% of eligible cross-section
    • Cash Flow50% pass✓ 6✗ 6▾

      5 of 10 pass — Buffett, Pabrai, Ackman +2 more object

      Free Cash Flow Proxy$-77.3M
      ✗BuffettPositive and growing
      FCF Positive and Growing$0.7M
      ✓LynchPositive and growing
      Operating Cash Flow$16.1M
      ✓PiotroskiCFO > 0
      (CFO / Total Assets) vs ROACFO/Assets=9.98%, ROA=-9.00%
      ✓PiotroskiCFO/Assets > ROA
      Price / (CFO / Shares)1.7x
      ✓Dreman< 8x
      P/E or FCF Yield
      ✗PabraiP/E < 15 or FCF Yield > 10%
      FCF Positive6/10 years FCF positive
      ✓MarksPositive FCF in majority of recent years
      (OCF - CapEx) / Market Cap
      ✗Ackman>= 4%
      Price / FCF per Share
      ✗Ackman<= 25
      Positive Operating Cash Flow frequency12/17 years positive
      ✓SleepPositive OCF in >= 70% of available years
      Operating Cash Flow - Capital Expenditures
      ✗Neff> $0 (app proxy for a strong fundamental case)
      (Operating cash flow - capex) / market capitalization
      ✗OshaughnessyTop 10% of eligible cross-section

    Business & financials

    Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

    Company Profile

    Industry: Food Products
    Size: Micro Cap($26.6M)
    Revenue: $342.3M+0.0% YoY
    Net Income: $14.5M+0.0% YoY

    Financial Snapshot

    Operating Margin-0.4%
    Return on Equity-33.3%
    Debt / Equity--
    Current Ratio1.20
    EPS (Diluted)$-0.68
    Shares Retired−1.5% / −1.5% 2y

    Shareholder Return

    Fiscal 2025

    Issued 1.5% of shares last year, 1.5% issued over two.

    Buybacks
    —
    Dividends
    —

    Company Financials

    Latest TTM and quarters alongside annual years

    TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

    The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

    MetricTTM · 2025-12-31

    2025-01-01 – 2025-12-31

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow, depreciation amortization, capex, revenue, net income, operating income, gross profit, ebit, pre tax income, interest expense.

    Q2 FY 2026

    2025-10-01 – 2025-12-31

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow, depreciation amortization, capex.

    Q1 FY 2026

    2025-07-01 – 2025-09-30

    Sources
    FY 2025
    Sources
    • 10-K · 2025-09-11
    FY 2024
    Sources
    • 10-K · 2025-09-11
    FY 2023
    Sources
    • 10-K · 2024-09-12
    FY 2022
    Sources
    • 10-K · 2023-09-12
    FY 2021
    Sources
    • 10-K · 2022-09-02
    Market Cap$26.6Mcurrent----$35.6Mest.$36.8Mest.$70.9Mest.$90.1Mest.$114.1Mest.
    Revenue$337.7M↓2%$88.9M↓1%$81.6M↓4%$342.3M$342.3M$341.1M$340.0M↑8%$314.8M
    Operating Income-$7.0M↓8%-$4.1M↓506%-$3.2M↓12%-$1.5M-$1.5M↑35%-$2.3M↑89%-$21.0M↓250%-$6.0M
    Net Income-$18.6M↓85%-$4.9M↓2417%-$4.0M↑20%-$14.5M-$14.5M↓275%-$3.9M↑95%-$79.2M↓406%-$15.7M
    EPS (Diluted)--$-0.22↓2300%$-0.19↑21%$-0.68$-0.68↓258%$-0.19↑89%$-1.74↓96%$-0.89
    Gross Margin40.7%↓2%36.3%↓16%39.7%↓9%43.5%43.5%↑11%39.3%↑16%33.7%↓21%42.5%
    Operating Margin-2.1%↓11%-4.7%↓511%-3.9%↓17%-0.4%-0.4%↑35%-0.7%↑89%-6.2%↓224%-1.9%
    ROE-52.2%↓115%——-33.3%-33.3%↓292%-8.5%↑96%-207.8%↓1290%-15.0%
    Total Debt$0↓100%$0↓100%$48.0K↓79%--$14.4M↓39%$23.5M↑2%$23.0M↓66%$66.8M
    Shareholders' Equity$35.7M↓14%$35.7M↓14%$40.0M↓2%$43.5M$43.5M↓4%$45.5M↑20%$38.1M↓64%$104.7M
    Current Ratio1.27↓1%1.27↓1%1.24↓6%1.201.20↓10%1.34↑1%1.32↓30%1.88
    Debt / Equity0.00↓100%0.00↓100%0.00↓79%—0.33↓36%0.52↓15%0.60↓5%0.64
    Operating Cash Flow$5.3M↑198%-$786.0K↓131%-$5.0M↓301%$16.1M$16.1M↑214%-$14.1M↓106%-$6.9M↑40%-$11.5M
    Free Cash Flow---$2.6M↓602%-$6.9M↓729%----------

    Score history

    Historical Score Timeline

    Industry peers

    Industry Peers

    Similar companies in Food Products

    FARM vs Peers — Financial Grading

    Revenue$342.3MBottom 25%
    Net Income$14.5MBottom 25%
    ROE-33.3%Bottom 25%
    D/E—
    Op. Margin-0.4%Bottom 25%
    Curr. Ratio1.20Median
    CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
    Mondelez International, Inc.MDLZ$85.5B$67.54$38.5B$2.5B9.5%0.729.2%0.592/93/93/70/3F-Score 64/11
    Archer-Daniels-Midland CoADM$34.7B$72.90$80.3B$1.1B4.7%0.33—1.375/92/91/70/3F-Score 55/11
    TYSON FOODS, INC.TSN$20.7B$58.82$54.4B$474.0M2.6%0.492.0%1.553/92/90/70/3F-Score 53/11
    GENERAL MILLS INCGIS$18.4B$34.32$18.4B$87.6M-1.2%1.834.8%0.683/94/90/71/3F-Score 52/11
    HORMEL FOODS CORP /DE/HRL$12.2B$22.09$12.1B$478.2M6.1%0.365.9%2.473/93/92/70/3F-Score 54/11
    Lamb Weston Holdings, Inc.LW$7.7B$56.06$6.6B$290.0M15.9%2.018.9%1.422/94/90/70/3F-Score 73/11
    SMITHFIELD FOODS INCSFD$7.6B$19.19$15.5B$987.0M14.5%0.298.3%2.976/93/93/73/3F-Score 68/11
    CONAGRA BRANDS INC.CAG$7.0B$14.73$11.3B$1.9B-30.1%1.14-14.4%0.903/90/91/70/3F-Score 44/11